TARG 9
Alternative Names: Alpha10-antibody drug conjugate - Targinta; TARG-9Latest Information Update: 09 Jun 2022
At a glance
- Originator Targinta
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma; Triple negative breast cancer
Most Recent Events
- 05 Apr 2022 Preclinical trials in Glioblastoma in Sweden (Parenteral) prior to April 2022
- 05 Apr 2022 Preclinical trials in Triple negative Breast cancer in Sweden (Parenteral) prior to April 2022
- 23 Jun 2020 Xintela receives preliminary patent approval for the treatment of brain tumors through the target integrin α10β1.